International Journal of Clinical Oncology

ISSN: 1341-9625

Journal Guideline

International Journal of Clinical Oncology Q1 Unclaimed

Springer Japan Japan

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

The International Journal of Clinical Oncology (IJCO) welcomes original and review papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Priority is given to high-quality clinical articles, including prospective randomized studies, rather than retrospective studies. Basic and translational studies will only be accepted if they have obvious clinical significance. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that their content has not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication. Why publish with us We are published in partnership with the Japan Society of Clinical Oncology. Our journal covers all areas of clinical oncology that report the results of novel and timely investigations, and we welcome reports on clinical trials, including prospective randomized studies. We provide a clear and supportive publication process, and ensure high visibility for your publication through marketing, societies, and libraries. It has an SJR impact factor of 0,95.

International Journal of Clinical Oncology focuses its scope in these topics and keywords: patients, response, therapy, molecular, cancer, cell, adjuvant, prognosis, clinical, nivolumab, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Medicine (miscellaneous) (Q1) Surgery (Q1) Hematology (Q2) Oncology (Q2)

Price

3190 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

0,95

SJR Impact factor

75

H Index

166

Total Docs (Last Year)

700

Total Docs (3 years)

5990

Total Refs

2137

Total Cites (3 years)

693

Citable Docs (3 years)

2.53

Cites/Doc (2 years)

36.08

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Nature Biomedical Engineering Q1
Journal of Thoracic Oncology Q1
Annual Review of Clinical Psychology Q1
Lancet Digital Health, The Q1
Journal of Experimental Medicine Q1

Compare this journals

Aims and Scope

Best articles by citations

Forty years? experience in surgical treatment for esophageal cancer

Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines

Docetaxel and carboplatin combination chemotherapy for recurrent endometrial cancer

Radiofrequency thermal ablation for treatment of hepatocellular carcinoma

Lymphadenopathy of sinus histiocytosis mimicking metastatic bladder cancer: a case report

Cytoreductive surgery combined with organ resection for advanced ovarian carcinoma

Salvage treatment with docetaxel for recurrent epithelial ovarian cancer

Therapeutic strategies for colorectal cancer in Europe and the United States: focus on chemotherapy for advanced colorectal cancer

Clinical outcomes of patients with epithelioid sarcomas: impact and management of nodal metastasis

Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU

Results of surgery for malignant fibrous histiocytomas of soft tissue

Definitive intraoperative radiotherapy for musculoskeletal sarcomas and malignant lymphoma in combination with surgical excision

SHOW MORE ARTICLES

Application of tyramide signal amplification for detection of N-glycolylneuraminic acid in human hepatocellular carcinoma

Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues

Loco-regional failures in head and neck cancer: can they be effectively salvaged by nonsurgical therapeutic modalities?

Development and clinical application of drug delivery systems for cancer treatment

Isolated internal mammary sentinel lymph node metastasis in two breast cancer patients

Bacillus Calmette?Guerin-refractory superficial bladder cancers: focus on pretreatment episodes

Results of treatment of retinoblastoma that has infiltrated the optic nerve, is recurrent, or has metastasized outside the eyeball

Locoregional adoptive immunotherapy resulted in regression in distant metastases of a recurrent esophageal cancer

A successful case of oral molecularly targeted therapy with imatinib for peritoneal metastasis of a gastrointestinal stromal tumor

Rapid and aggressive recurrence accompanied by portal tumor thrombus after radiofrequency ablation for hepatocellular carcinoma

Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma

Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy